MANGOCEUTICALS, INC. Reports Equity Sale and Officer Changes
Ticker: MGRX · Form: 8-K · Filed: Aug 23, 2024 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Aug 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $500,000, $1,100, $0.15, $1,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, management-change, corporate-governance
TL;DR
Mangoceuticals sold unregistered equity and shuffled execs/directors. Watch for dilution and strategy shifts.
AI Summary
On August 22, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing the unregistered sale of equity securities. The filing also announced changes in its board and officer positions, including the departure of certain directors and officers, the election of new directors, and adjustments to compensatory arrangements for its officers. Specific details regarding the equity sale and the individuals involved in the personnel changes were not provided in the excerpt.
Why It Matters
This filing indicates potential dilution from equity sales and significant changes in corporate leadership, which could impact the company's strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Unregistered equity sales can signal financial distress or dilutive financing, while changes in leadership introduce uncertainty.
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- August 22, 2024 (date) — Date of Report
- Texas (location) — State of Incorporation
- Dallas (location) — Business Address City
- 75248 (postal_code) — Business Address Zip
FAQ
What type of equity securities were sold?
The filing indicates an 'Unregistered Sales of Equity Securities' but does not specify the type of securities in the provided excerpt.
Were there any material changes to MANGOCEUTICALS, INC.'s executive compensation as a result of the officer changes?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, suggesting potential changes, but specific details are not in the excerpt.
Who are the newly elected directors or departing officers?
The filing notes 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not name the individuals involved in the provided excerpt.
What is the total number of shares or the aggregate dollar amount of the unregistered equity securities sold?
The provided excerpt does not contain specific figures for the number of shares or the dollar amount of the unregistered equity securities sold.
What is the reason for the unregistered sale of equity securities?
The filing does not state the specific reason for the unregistered sale of equity securities in the provided excerpt.
Filing Stats: 984 words · 4 min read · ~3 pages · Grade level 13.8 · Accepted 2024-08-23 16:41:13
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $500,000 — d Stock (" Fourth Closing Shares ") for $500,000 in connection with a partial closing of
- $1,100 — ck each have an initial stated value of $1,100 per share, and as a result, the effecti
- $0.15 — lder thereof, based on a floor price of $0.15 per share. Item 5.02 Departure of Dir
- $1,500 — and Mr. Cohen on August 31, 2022, from $1,500 to $2,500 per month. SIGNATURES Pur
- $2,500 — ohen on August 31, 2022, from $1,500 to $2,500 per month. SIGNATURES Pursuant to t
Filing Documents
- form8-k.htm (8-K) — 42KB
- 0001493152-24-033739.txt ( ) — 217KB
- nasdaq-20240822.xsd (EX-101.SCH) — 3KB
- nasdaq-20240822_lab.xml (EX-101.LAB) — 33KB
- nasdaq-20240822_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: August 23, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer